Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Healthcare News.
Press releases published on July 16, 2025
Safety Shot Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCOTTSDALE, AZ, July 16, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced it has received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") …
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic …
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Full Alliance Group Launches Development of YAHBEE SHOPPING NETWORK — A Web3-Driven, Peer-to-Peer Commerce Revolution
TAMPA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) (“the Company”), through its majority-owned subsidiary Qubitera Holdings, proudly announces the launch of the YAHBEE SHOPPING NETWORK — a groundbreaking platform that …
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel …
Chiesi and Plug and Play Call for Innovative Solutions to Revolutionize Respiratory Care in the U.S.
CARY, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Chiesi, an international biopharmaceutical company (Chiesi Group) and Plug and Play, the world’s largest Open Innovation platform, announced today the launch of Breathing Innovation: The Chiesi Challenge for …
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on …
ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes
LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the company’s official website, www.viaderma.com. Due to the company …
As the Americans with Disabilities Act turns 35, Joni Eareckson Tada’s advocacy continues
Agoura Hills, CA, July 16, 2025 (GLOBE NEWSWIRE) -- For 35 years, the Americans with Disabilities Act has ensured legal safeguards that protect people with disabilities from discrimination in employment, education, transportation and other aspects of …
Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases
Amid momentum, the company generates millions in new high-margin revenue for diagnostic network Introduces AI application suites to demonstrate the future of pathology for high-impact use cases Launches 24/7 support to meet the demands of mission-critical, …
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for …
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19) 12-month overall survival of 88% …
Vantive and Innovative Renal Care Enter into a Long-Term Agreement Focused on Enhanced Use of Technology to Expand Home Dialysis Therapies
DEERFIELD, Ill. and FRANKLIN, Tenn., July 16, 2025 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, and Innovative Renal Care (IRC), a comprehensive kidney care provider for patients across the U.S …
Qualigen Granted New Patents Covering 25 Countries
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides …
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive …
Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio
SOUTH SAN FRANCISCO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies for unmet needs in the neurodegenerative diseases, …
Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025
TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after …
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as …
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term …
Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call
DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on …